Timing of Alzheimer's disease biomarker progressions: A two-decade observational study from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2024-10-21 DOI:10.1002/alz.14306

Tamar Schaap, Pamela Thropp, Duygu Tosun

引用次数: 0

Abstract

Alzheimer's Disease Neuroimaging Initiative (ADNI) has been pivotal in identifying and refining Alzheimer's disease (AD) biomarkers for clinical trials. This study leverages longitudinal data from participants who have progressed to amyloid-positivity during their study participation to track evolution of biomarkers and cognitive function.

查看原文本刊更多论文

阿尔茨海默病生物标志物进展的时间：阿尔茨海默病神经影像学倡议（ADNI）的一项长达二十年的观察研究

阿尔茨海默病神经影像倡议（ADNI）在为临床试验确定和完善阿尔茨海默病（AD）生物标志物方面发挥了关键作用。这项研究利用参与者在参与研究期间发展为淀粉样蛋白阳性的纵向数据来跟踪生物标记物和认知功能的演变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.